Business Update23 Jan 2024, 11:03 pm
Glenmark Life Sciences Reports Quality Revenue Growth of 5.9% YoY
AI Summary
Glenmark Life Sciences Limited (GLS) has announced its financial results for the quarter and nine months ended December 31, 2023. The company has reported a revenue growth of 5.9% YoY, with EBITDA growing 14.6% YoY and EBITDA margins at 30.4%. The company has also signed a multi-year definitive agreement to supply APIs for an innovator's product and has witnessed strong orderbook for external business.,
Key Highlights
- Revenue growth of 5.9% YoY
- EBITDA growth of 14.6% YoY
- EBITDA margins at 30.4%
- Signed a multi-year definitive agreement for API supply
- Strong orderbook for external business